Kalbe Farma KLBF IJ -Buy- Transforming the brand
Consumer health is a very crucial division for KLBF, as it possesses the highest margin,
Consumer Durables JW SH SC 1.1K 27th Sep, 2024
Continues to be the best FMCG-story stock play in Indonesia
AMRT has consistently outperformed its FMCG peers in terms of sales growth over the past decade (Fig. 2). We believe this can be primarily attributed to its ability to curate top-selling FMCG products and capitalize on the robust consumption growth in regions outside of Java (refer to Fig. 3 and our earlier note Regions with faster consumption growth in focus). While the growth trajectory is intact, we believe there remains potential for further improvement in operating leverage for AMRT (Fig. 4).
AMRT has actively focused on enhancing efficiency through initiatives such as: 1) optimizing employee allocation, 2) expanding chiller infrastructure to capture the higher-margin and foot-traffic-generating segments such as beverages and ready-to-eat products, and 3) improving cash collection systems. These efforts may temporarily increase operating expenses, but we anticipate long-term benefits, especially given AMRT's relatively low net profit margin (NPM) compared with its regional peers (Fig. 5).
Some excitement likely in 3Q24F
Although overall 1H24 same-store sales growth (SSSG) was in line with our expectation at 4.7% y-y, we anticipate stronger performance in 3Q24F. We estimate Alfamart's SSSG could potentially reach mid-to-high single-digit growth, driven by encouraging trends observed in Alfamidi's (MIDI IJ, Buy) Jul-Aug SSSG, particularly in ex-Java regions. While Alfamart may not fully match Alfamidi's SSSG due to lower ex-Java revenue contribution (Fig. 7), it aligns with the broader strength in mini market FMCG sales (Fig. 6).
While we expect gross profit margin (GPM) to be stable, opex as a percentage of sales will likely remain elevated due to ongoing efficiency initiatives. However, we believe Alfamart is well-positioned to deliver strong results in 3Q24F (Fig. 1). Note that historically, 4Q has contributed approximately 40% of AMRT’s annual profit, primarily driven by year-end rebates from suppliers.
Maintain Buy rating and TP of IDR3,830, implying ~17% upside
Our TP of IDR3,830 is based on a 2025F P/E of 33.4x, +1SD above its five-year average. AMRT's ability to select and curate the best FMCG products remains a key advantage, making it a prime proxy for capturing the FMCG market in Indonesia. The stock has also attracted significant foreign inflows YTD (Fig. 8 and 9). A potential downside risk is a slowdown in demand for fee-based transactions. Currently, the stock trades at 28.6x 2025F P/E.
INVESTMENT RATINGS
A rating of ‘Buy’, indicates that the analyst expects the stock to outperform the Benchmark over the next 12 months. A rating of ‘Neutral’, indicates that the analyst expects the stock to perform in line with the Benchmark over the next 12 months. A rating of ‘Reduce’, indicates that the analyst expects the stock to underperform the Benchmark over the next 12 months. A rating of ‘Suspended’, indicates that the rating, target price, and estimates have been suspended temporarily to comply with applicable regulations and/or firm policies. Securities and/or companies that are labelled as ‘Not Rated’ or ‘No Rating’ are not in regular research coverage. Benchmark is Indonesia Composite Index (‘IDX Composite’). A ‘Target Price’, if discussed, indicates the analyst’s forecast for the share price with a 12-month time horizon, reflecting in part of the analyst’s estimates for the company’s earnings, and may be impeded by general market and macroeconomic trends, and by other risks related to the company or the market in general.
GENERAL DISCLOSURE/DISCLAIMER
This report is prepared by PT Verdhana Sekuritas Indonesia (“PTVSI”) a securities company registered in Indonesia, supervised by Indonesia Financial Services Authority (OJK) and a member of the Indonesia Stock Exchange (IDX).
This report is intended for client of PTVSI only and no part of this document may be (i) copied, photocopied or duplicated in any form or by any means or (ii) redistributed without the prior written consent of PTVSI.
The research set out in this report is based on information obtained from sources believed to be reliable, but PTVSI do not make any representation or warranty as to its accuracy, completeness or correctness. The information in this report is subject to change without notice, its accuracy is not guaranteed, it may be incomplete or condensed and it may not contain all material information concerning the company (or companies) referred to in this report. Any information, valuations, opinions, estimates, forecasts, ratings or targets herein constitutes a judgment as of the date of this report is published, and there is no assurance that future results or events will be consistent.
This report is not to be construed as an offer or a solicitation of an offer to buy or sell any securities or financial products. PTVSI and its associates, its directors, and/or its employees may from time to time have interests in the securities mentioned in this report or it may or will engage in any securities transaction or other capital market services for the company (companies) mentioned herein.
ANALYST CERTIFICATION
The research analyst primarily responsible for the content of this report and certifies that the views about the companies including their securities expressed in this report accurately reflect his/her personal views. The analyst also certifies that no part of his/her compensation was, is, or will be, directly, or indirectly, related to specific recommendations or views expressed in this report.
RESTRICTIONS ON DISTRIBUTION
By accepting this report, the recipient hereof represents and warrants that you are entitled to receive such report in accordance with the restrictions and agrees to be bound by the limitations contained herein. Neither this report nor any copy hereof may be distributed except in compliance with applicable Indonesian capital market laws and regulations.
Rating Remains | Buy |
Target price Remains | IDR 3,830 |
Closing price 26 September 2024 | IDR 3,280 |
Jody Wijaya (jody.wijaya@verdhana.id)
Sandy Ham (sandy.ham@verdhana.id)
Samuel Christian (samuel.christian@verdhana.id)